IBA signs Binding Term Sheet with Medtechnica Ltd for two Proteus®ONE proton therapy solutions at the Tel Aviv Sourasky Medical Center in Israel
22 Mai 2023 - 7:00AM
IBA signs Binding Term Sheet with Medtechnica Ltd for two
Proteus®ONE proton therapy solutions at the Tel Aviv Sourasky
Medical Center in Israel
Louvain-La-Neuve, Belgium, May 22, 2023
– IBA (Ion Beam Applications S.A., EURONEXT), the world
leader in particle accelerator technology and the world’s leading
provider of proton therapy solutions for the treatment of cancer,
today announces it has signed a Binding Term Sheet with Medtechnica
Ltd for the installation of two Proteus®ONE1 compact proton
therapy solutions at the Sourasky Medical Center (Ichilov Hospital)
in Tel Aviv, Israel.
Sourasky Medical Center has been selected by the
Israeli Ministry of Health to host the first national proton
therapy center in Israel, bringing this cutting-edge technology to
hundreds of patients per year. The project is fully financed and
IBA expects to receive the first payment in the coming weeks.
The integrated solution includes two
Proteus®ONE1 systems as well as a fully integrated
quality assurance (QA) hardware and software package from IBA
Dosimetry. Once approved by regulatory authorities, IBA will
upgrade the two systems with DynamicARC®2, IBA’s unique Arc Proton
Therapy solution. The contract includes long-term operation and
maintenance services to be provided by IBA. Sourasky Medical Center
expects to start treating patients in 2026.
The two side-by-side single room solutions
configuration has been designed to optimize clinical availability
and patient treatment. Full independence of the two treatment rooms
will lead to optimized clinical availability, and full redundancy
in case of maintenance or upgrades.
The typical end-user price for one Proteus®ONE
system with a multi-year maintenance contract ranges between EUR 45
and 50 million.
Olivier Legrain, Chief Executive Officer
of IBA, commented: “This project further demonstrates our
position as a global market leader in proton therapy, with
increasing interest from the EMEA region. This will be the first
proton therapy system to be installed in Israel and the second two
Proteus®ONE solutions to be installed side-by-side worldwide. This
contract also demonstrates that multiple Proteus®ONE systems are
the solution of choice for comprehensive oncology centers, a
solution that is scalable, expandable, and future proof. Sourasky
Medical Center is renowned for its innovative cancer treatments,
and we look forward to supporting the center in our joint mission
of providing cancer patients with access to the most advanced
treatment options.”
Professor Ronni Gamzu, Director of the
Tel Aviv Sourasky Medical Center, added: “The choice of
the IBA Proteus®️ONE solution was obvious when purchasing the
world’s most advanced proton accelerators for the National Center
for Proton Therapy at the Adelson Cancer Tower that is currently
being established at the Ichilov Hospital. With the support of the
Israeli Ministry of Health, this is another huge step on the way to
establishing one of the most advanced national centers in the world
for proton therapy, in Israel.”
***ENDS***
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 1,800 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
About Ichilov Hospital / Sourasky Medical
Center
Tel Aviv Sourasky Medical Center (Ichilov) is
the largest acute care facility in Israel, treating about 400,000
patients and hosting 1.8 million patient visits per year. A
1500-bed world-class governmental academic medical center, Tel Aviv
Sourasky Medical Center serves a population of one million people,
including residents from the greater Tel Aviv area and visitors to
the metropolis.
About MedTechnica Ltd
Founded in 1953, Medtechnica specializes in
importing, marketing, sales and technical support of medical
devices and equipment. A subsidiary of the Ilex
Group (TASE:ILX), the company partners with international
blue-chip companies healthcare professionals and purchasing
departments to provide them with holistic solutions for the Israeli
market. Our customers include HMOs, public hospitals, the Ministry
of Health, the Ministry of Defense, the Israeli Police Department,
and private health institutions and clinics, as well as
private customers.
CONTACTSSoumya
ChandramouliChief Financial Officer+32 10
475 890Investorrelations@iba-group.com
Olivier LechienCorporate
Communication Director+32 10 475 890communication@iba-group.com
Consilium Strategic
CommunicationsAmber Fennell, Matthew Neal, Lucy
Featherstone+44 (0) 20 3709 5700IBA@consilium-comms.com
1 Proteus®ONE is the brand name of Proteus®235
2 DynamicARC® is a registered brand of the IBA’s Proton Arc
therapy solution currently under development phase.
- 230519-IBA-2ProteusONE-Ichilov-Israel-EN
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024